The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 17, 2015
Filed:
Jul. 15, 2010
Dinah W. Y. Sah, Cambridge, MA (US);
Andrei P. Guzaev, Escondido, CA (US);
Matthew H. Adams, Zimmerman, MN (US);
Pei GE, Cambridge, MA (US);
Muthiah Manoharan, Cambridge, MA (US);
Douglas Ulen Gwost, Shoreview, MN (US);
Gregory Robert Stewart, Plymouth, MN (US);
David Kent Stiles, Maple Grove, MN (US);
Brian Dale Nelson, Birchwood, MN (US);
William Frederick Kaemmerer, Edina, MN (US);
Don Marshall Gash, Lancaster, KY (US);
Dinah W. Y. Sah, Cambridge, MA (US);
Andrei P. Guzaev, Escondido, CA (US);
Matthew H. Adams, Zimmerman, MN (US);
Pei Ge, Cambridge, MA (US);
Muthiah Manoharan, Cambridge, MA (US);
Douglas Ulen Gwost, Shoreview, MN (US);
Gregory Robert Stewart, Plymouth, MN (US);
David Kent Stiles, Maple Grove, MN (US);
Brian Dale Nelson, Birchwood, MN (US);
William Frederick Kaemmerer, Edina, MN (US);
Don Marshall Gash, Lancaster, KY (US);
Medtronic, Inc., Minneapolis, MN (US);
Abstract
This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.